NCT02058446

PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension

An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: TSH Biopharm Corporation Limited · Industry
• Sex: All
• Age: 20 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in worldwide populations including Asian patients. The study primarily aims to evaluate the effectiveness of Amlodipine/Valsartan combination in patients with essential hypertension in Taiwan using a prospective, open-label, non-randomized approach. The study also wants to investigate the safety of Amlodipine/Valsartan combination during the 6-week treatment period.

Conditions

• Essential Hypertension

Interventions

Type	Name	Description
DRUG	Amlodipine/Valsartan	Amlodipine/Valsartan: 5 mg/80 mg

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-03-01
• Completion: 2014-03-01
• First posted: 2014-02-10
• Last updated: 2015-11-13

Locations

1 site across 1 country: Taiwan